Zhihang Chen1, Marie-France Penet1, Sridhar Nimmagadda1, Cong Li1, Sangeeta Ray1, Paul T. Winnard Jr.1, Dmitri Artemov1, Kristine Glunde1, Martin G. Pomper1, Zaver M. Bhujwalla1
Prostate cancer (PCa) is the second leading cause of death from cancer in men in the U.S. The vast majority of men dying of PCa succumb to metastatic androgen-refractory disease. There is therefore a compelling need to find effective treatments for metastatic PCa. In theranostics, noninvasive imaging-based detection of a target is combined with the delivery of a therapeutic payload to the target. Here we are combining prostate-specific membrane antigen (PSMA) based detection of metastatic PCa with a theranostic PSMA-targeted prototype nanoplex carrying multimodality imaging reporters together with small interfering RNA (siRNA) and a prodrug enzyme.